{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:55:38Z","timestamp":1790016938817,"version":"4.0.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings. To date, anti-BoNT therapy is reduced to the use of horse hyperimmune serum, which causes many side effects, as well as FDA-approved drug BabyBig which consists of human-derived anti-BoNT antibodies (IgG) for infant botulinum treatment. Therapeutics for botulism treatment based on safer monoclonal antibodies are undergoing clinical trials. In addition, agents have been developed for the specific prevention of botulism, but their effectiveness has not been proved. In this work, we have obtained a recombinant adeno-associated virus (rAAV-B11-Fc) expressing a single-domain antibody fused to the human IgG Fc-fragment (B11-Fc) and specific to botulinum toxin type A (BoNT\/A). We have demonstrated that B11-Fc antibody, expressed <jats:italic>via<\/jats:italic> rAAV-B11-Fc treatment, can protect animals from lethal doses of botulinum toxin type A, starting from day 3 and at least 120 days after administration. Thus, our results showed that rAAV-B11-Fc can provide long-term expression of B11-Fc-neutralizing antibody <jats:italic>in vivo<\/jats:italic> and provide long-term protection against BoNT\/A intoxication. Consequently, our study demonstrates the applicability of rAAV expressing protective antibodies for the prevention of intoxication caused by botulinum toxins.<\/jats:p>","DOI":"10.3389\/fmicb.2022.960937","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T06:16:45Z","timestamp":1664259405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis"],"prefix":"10.3389","volume":"13","author":[{"given":"Artem A.","family":"Derkaev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina I.","family":"Ryabova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias B.","family":"Esmagambetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry V.","family":"Shcheblyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A.","family":"Godakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina D.","family":"Vinogradova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly N.","family":"Noskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Y.","family":"Logunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris S.","family":"Naroditsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Gintsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","volume-title":"Molecular Biology of the Cell","author":"Alberts","year":"2002"},{"key":"B2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mt.6300344","article-title":"Rapid\/sustained anti-anthrax passive immunity mediated by co-administration of Ad\/AAV","volume":"16","author":"De","year":"2008","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.32607\/actanaturae.11487","article-title":"Nanobodies are potential therapeutic agents for the ebola virus infection","volume":"13","author":"Esmagambetov","year":"2021","journal-title":"Acta Nat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0174187","DOI":"10.1371\/journal.pone.0174187","article-title":"Three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes","volume":"12","author":"Fan","year":"2017","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.mt.6300142","article-title":"An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo","volume":"15","author":"Fang","year":"2007","journal-title":"Mol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"822159","DOI":"10.3389\/fimmu.2022.822159","article-title":"L. Single-domain antibodies efficiently neutralize SARSCoV-2 variants of concern","volume":"3","author":"Favorskaya","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/protein\/gzq111","article-title":"Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin","volume":"24","author":"Garcia-Rodriguez","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/toxins10030105","article-title":"Three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes","volume":"10","author":"Garcia-Rodriguez","year":"2018","journal-title":"Toxins"},{"key":"B11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/toxins11080464","article-title":"Camelid VHHs fused to human fc fragments provide long term protection against botulinum neurotoxin A in mice","volume":"11","author":"Godakova","year":"2019","journal-title":"Toxins"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e112268","DOI":"10.1371\/journal.pone.0112268","article-title":"Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression","volume":"9","author":"Greig","year":"2014","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","article-title":"Selection of an Efficient AAV vector for robust CNS transgene expression","volume":"15","author":"Hanlon","year":"2019","journal-title":"Mol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1016\/j.vaccine.2005.05.017","article-title":"Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins","volume":"23","author":"Harmsen","year":"2005","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/nnm.13.86","article-title":"Nanobodies and their potential applications","volume":"8","author":"Hassanzadeh-Ghassabeh","year":"2013","journal-title":"Nanomedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.idc.2011.07.005","article-title":"Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases","volume":"25","author":"Hsu","year":"2011","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymthe.2004.10.018","article-title":"Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody","volume":"11","author":"Kasuya","year":"2005","journal-title":"Mol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bit.20562","article-title":"PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization","volume":"92","author":"Lee","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"B20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CMR.19.2.298-314.2006","article-title":"Laboratory diagnostics of botulism","volume":"19","author":"Lindstr\u00f6m","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/acscentsci.0c01448","article-title":"The masking game: design of activatable antibodies and mimetics for selective therapeutics and cell control","volume":"7","author":"Lucchi","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/toxins12050302","article-title":"Fully human monoclonal antibodies effectively neutralizing botulinum neurotoxin serotype B","volume":"12","author":"Matsumura","year":"2020","journal-title":"Toxins"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/mt.2013.134","article-title":"AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells","volume":"22","author":"Mays","year":"2014","journal-title":"Mol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e106422","DOI":"10.1371\/journal.pone.0106422","article-title":"Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein","volume":"9","author":"Mukherjee","year":"2014","journal-title":"PLoS ONE"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11664","DOI":"10.1038\/s41598-022-15876-2","article-title":"Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes","volume":"12","author":"Mukherjee","year":"2022","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e29941","DOI":"10.1371\/journal.pone.0029941","article-title":"Novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model","volume":"7","author":"Mukherjee","year":"2012","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/BTT.S127099","article-title":"Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent clostridium difficile infection","volume":"12","author":"Navalkele","year":"2018","journal-title":"Biologics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vectors vaccines against infectious diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody","volume":"99","author":"Nowakowski","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/toxins9100309","article-title":"The European AntibotABE framework program and its update: development of innovative botulinum antibodies","volume":"9","author":"Rasetti-Escargueil","year":"2017","journal-title":"Toxins"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Rivi\u00e8re","year":"2006","journal-title":"Gene Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.30895\/2221-996X-2021-21-4-266-278","article-title":"Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale","volume":"21","author":"Ryabova","year":"2021","journal-title":"BIOpreparations"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/sj.gt.3301858","article-title":"Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector specific immune response","volume":"9","author":"Sailaja","year":"2002","journal-title":"Gene Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1128\/IAI.01084-09","article-title":"Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents","volume":"78","author":"Sepulveda","year":"2010","journal-title":"Infect. Immun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"104617","DOI":"10.1016\/j.antiviral.2019.104617","article-title":"Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection","volume":"172","author":"Shcheblyakov","year":"2019","journal-title":"Antiviral Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2008.04.016","article-title":"Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV","volume":"378","author":"Skaricic","year":"2008","journal-title":"Virology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01270","DOI":"10.1128\/AAC.01270-19","article-title":"Safety and pharmacokinetics of a four monoclonal antibody combination against botulinum C and D neurotoxins","volume":"63","author":"Snow","year":"2019","journal-title":"Antimicrob"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1128\/IAI.00856-08","article-title":"Adenovirus-mediated delivery of an anti-v antigen monoclonal antibody protects mice against a lethal yersinia pestis challenge","volume":"77","author":"Sofer-Podesta","year":"2009","journal-title":"Infect. Immun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00216-010-3905-3","article-title":"Llama-derived single-domain antibodies for the detection of botulinum A neurotoxin","volume":"398","author":"Swain","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.toxicon.2010.07.003","article-title":"Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases","volume":"56","author":"Tremblay","year":"2010","journal-title":"Toxicon"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1128\/IAI.01033-13","article-title":"Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2","volume":"81","author":"Tremblay","year":"2013","journal-title":"Infection And Immun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1128\/CVI.05261-11","article-title":"Equine botulinum antitoxin for the treatment of infant botulism","volume":"18","author":"Vanella de Cuetos","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e132891","DOI":"10.1172\/jci.insight.132891","article-title":"Symptomatic treatment of botulism with a clinically approved small molecule","volume":"5","author":"Vazquez-Cintron","year":"2020","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/s41598-019-39890-z","article-title":"TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens","volume":"9","author":"Venkatasubramaniam","year":"2019","journal-title":"Sci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.32607\/actanaturae.11495","article-title":"Development of neutralizing nanobodies to the hemagglutinin stem domain of influenza A viruses","volume":"13","author":"Voronina","year":"2021","journal-title":"Acta Naturae"},{"key":"B53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1359-6446(99)01433-6","article-title":"Adenovirus technology for gene manipulation and functional studies","volume":"5","author":"Wang","year":"2000","journal-title":"Drug Discov. Today"},{"key":"B54","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/1087057109343206","article-title":"Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library","volume":"14","author":"Yu","year":"2009","journal-title":"J. Biomol. Screen."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1099\/vir.0.83670-0","article-title":"Delivery of single-chain antibodies (ScFvs) directed against the 37\/67 KDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy","volume":"89","author":"Zuber","year":"2008","journal-title":"J. Gen. Virol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.960937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T06:16:47Z","timestamp":1664259407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.960937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":55,"alternative-id":["10.3389\/fmicb.2022.960937"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.960937","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"960937"}}